DHTKD1 and cancer: Accordingly, we devised a strategy that employed two different cancer-selective promoters to independently drive Ad.5 E1A and luciferase. For this purpose, we retained the minimal PEG-3 promoter to drive the Ad.5 E1A gene and chose a truncated tCCN1-promoter that displays elevated expression in cancer cells [64], to drive luciferase gene expression, while again retaining the CMV-driven mda-7/IL-24 gene, i.e., an Ad.5-TCTV (Figure 1).